204885 Complement C3, Human

204885
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
204885-250UG
Retrieving availability...
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 250 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewNative, human C3 complement component. Glycoprotein composed of two non-identical disulfide-bonded subunits with M.W. of 115 kDa (α) and 75 kDa (β). Present in normal human serum at 1.25 mg/ml. Classical and alternative activation pathways of complement converge at C3 step. Activation via either pathway can result in assembly of C3-cleaving enzymes (C3 convertases) on target surfaces. Both C3 convertases cleave the C3 α-chain at peptide bond 77 resulting in production of C3a (M.W. 9083) and C3b fragments (M.W. 180,000). Released C3a peptide is one of the three complement anaphylatoxins. The nascent C3b fragment can form a covalent ester bond with target surface. This covalent attachment of C3b to target acceptors is required for continuation of complement activation.
      Catalogue Number204885
      Brand Family Calbiochem®
      References
      ReferencesLambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.
      Product Information
      CAS number80295-41-6
      FormLiquid
      FormulationIn PBS.
      Quality LevelMQ100
      Applications
      Biological Information
      Biological activity>3,000 C₃H₅0 units/mg; ≥60% of the C3 activity in normal human serum on a mg/mg basis.
      Purity≥85% by SDS-PAGE
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Physicochemical Information
      ContaminantsIgG, IgA, IgM, C4, functionally active C5, albumin or ceruloplasmin: ≤trace amounts
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Complement C3, Human SDS

      Title

      Safety Data Sheet (SDS) 

      Complement C3, Human Certificates of Analysis

      TitleLot Number
      204885

      References

      Reference overview
      Lambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.

      Citations

      Title
    • Inal, J.M. and Schifferli J.A., 2002. Journal of Immunology 168, 5213.
    • Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision29-June-2018 JSW
      DescriptionNative, human C3 complement component. Glycoprotein composed of two non-identical disulfide-bonded subunits with M.W. of 115,000 (α) and 75,000 (β). Present in normal human serum at 1.25 mg/ml. Classical and alternative activation pathways of complement converge at the C3 step. Activation via either pathway can result in assembly of C3-cleaving enzymes (C3 convertases) on target surfaces. Both C3 convertases cleave the C3 α-chain at peptide bond 77, resulting in production of C3a (M.W. 9083) and C3b fragments (M.W. 180,000). Released C3a peptide is one of the three complement anaphylatoxins. The nascent C3b fragment can form a covalent ester bond with target surface. The covalent attachment of C3b to target acceptors is required for continuation of complement activation.
      FormLiquid
      FormulationIn PBS.
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      CAS number80295-41-6
      Purity≥85% by SDS-PAGE
      ContaminantsIgG, IgA, IgM, C4, functionally active C5, albumin or ceruloplasmin: ≤trace amounts
      Biological activity>3,000 C₃H₅0 units/mg; ≥60% of the C3 activity in normal human serum on a mg/mg basis.
      Storage ≤ -70°C
      Avoid freeze/thaw
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesLambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.
      Citation
    • Inal, J.M. and Schifferli J.A., 2002. Journal of Immunology 168, 5213.